References
- Aronoff G. R., Ozawa T., DeSante K. A., Nash J. F., Ridolfo A. S. Benoxaprofen kinetics in renal impairment. Clinical Pharmacology and Therapeutics 1982; 32: 190–194
- Berry D. J., Parke D. V. The disposition of feprazone and its hydroxylated metabolite in human volunteers. Xenobiotica 1988a; 18: 857–868
- Berry D. J., Parke D. V. The micro gas-liquid chromatographic analysis of 4-(3′,3′-dimethylallyl)-1,2-(diphenylpyrazolidine)-3,5-dione (feprazone) in human biosamples. Journal of Pharmaceutical and Biomedical Analysis 1988b; 6: 493–501
- Billings R., Burry H. C., Grahame R., Berry D. J., Donovan B. A double-blind cross-over trial of prenazone and aspirin in the management of rheumatoid arthritis. Rheumatology and Rehabilitation 1975; 14: 61–70
- Cassadio S., Pala G., Marazzi-Uberti E., Lumachi B., Crescenzi E., Donetti A., Mantegani A., Bianchi C. Terpene compounds as drugs. X. 4-Prenyl-l,2-diphenyl-3,5-pyrazolidinedione (DA2370): a new anti-inflammatory drug, with low ulcerogenic effects, derived from a series of terpenyl pyrazblidinediones. Arzneimittel-Forschung 1972; 22: 171–174
- Crooks J., O'Malley K., Stevenson I. H. Pharmacokinetics in the elderly. Clinical Pharmacokinetics 1976; 1: 280–296
- Donetti A., Quintero M. G., Cereda E., Yamaguchi H. Mass spectrometricidentification of feprazone metabolites in rat, dog and man. Recent Developments in Mass Spectrometry in Biochemistry and Medicine, A. Frigerio, M. McCamish. Elsevier, Amsterdam 1980; Vol. 6: 203–215
- Eason C. T., Bonner F. W., Parke D. V. The importance of pharmacokinetic and receptor studies in drug safety evaluation. Regulatory Toxicology and Pharmacology 1990; 11: 288–307
- Fletcher M. R., Loebl W., Scott J. T. Feprazone, a new anti-inflammatory agent. Studies of potency and gastrointestinal tolerance. Annals of Rheumatic Diseases 1975; 34: 190–194
- Gaetani M., Yamaguchi H., Vidi A., Hashimoto Y., Donnetti A. Species differences in the metabolism of feprazone, an anti-inflammatory drug. Pharmacologic Research Communications 1979; 11: 719–730
- Haslock I., Burkinshaw L., Berry D. J., Donovan B., Wright V. Some studies of feprazone. Rheumatology and Rehabilitation 1976; 15: 81–86
- Laurent M. R., Berry D., Grahame R. Feprazone in osteoarthritis: comparison of twice and 3-times daily dosage regimens. Pharmatherapeutica 1983; 3: 393–397
- O'Malley K., Crooks J., Duke E., Stevenson I. H. Effect of age and sex on human drug metabolism. British Medical Journal 1971; 3: 607–609
- Parke D. V. Adverse effects of drugs. Journal of the Royal Society of Health 1985; 105: 39–46
- Triggs E. J., Nation R. L. Pharmacokinetics in the aged: a review. Journal of Pharmacokinetics and Biopharmacy 1975; 3: 387–418
- Triggs E. J., Nation R. L., Long A., Ashley J. J. Pharmacokinetics and the elderly. European Journal of Clinical Pharmacology 1975; 8: 55–62